213 related articles for article (PubMed ID: 33396624)
1. UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR.
Chiang AJ; Li CJ; Tsui KH; Chang C; Chang YI; Chen LW; Chang TH; Sheu JJ
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33396624
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase (FASN) inhibits the cervical squamous cell carcinoma (CESC) progression through the Akt/mTOR signaling pathway.
Lin Q; Jiang Y; Zhou F; Zhang Y
Gene; 2023 Jan; 851():147023. PubMed ID: 36375657
[TBL] [Abstract][Full Text] [Related]
3. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
[TBL] [Abstract][Full Text] [Related]
4. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
5. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.
Lv Z; Wang M; Hou H; Tang G; Xu H; Wang X; Li Y; Wang J; Liu M
Int J Biol Sci; 2023; 19(11):3293-3306. PubMed ID: 37496990
[No Abstract] [Full Text] [Related]
6. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.
Shen Z; Jiang X; Zeng C; Zheng S; Luo B; Zeng Y; Ding R; Jiang H; He Q; Guo J; Jie W
BMC Cancer; 2013 Apr; 13():192. PubMed ID: 23587173
[TBL] [Abstract][Full Text] [Related]
7. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway.
Lu ZN; Song J; Sun TH; Sun G
Chin Med J (Engl); 2021 Oct; 134(20):2465-2474. PubMed ID: 34620747
[TBL] [Abstract][Full Text] [Related]
8. UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
Palumbo A; Da Costa NM; De Martino M; Sepe R; Pellecchia S; de Sousa VP; Nicolau Neto P; Kruel CD; Bergman A; Nasciutti LE; Fusco A; Pinto LF
Oncotarget; 2016 Oct; 7(40):65876-65887. PubMed ID: 27588470
[TBL] [Abstract][Full Text] [Related]
9. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
10. UBE2C is involved in the functions of ECRG4 on esophageal squamous cell carcinoma.
Li L; Li X; Wang W; Gao T; Shi Z
Biomed Pharmacother; 2018 Feb; 98():201-206. PubMed ID: 29268240
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
12. Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death.
Guo L; Ding Z; Huang N; Huang Z; Zhang N; Xia Z
Cell Cycle; 2017 Sep; 16(18):1705-1718. PubMed ID: 28767320
[TBL] [Abstract][Full Text] [Related]
13. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Liang J; Nishi H; Bian ML; Higuma C; Sasaki T; Ito H; Isaka K
Oncol Rep; 2012 Oct; 28(4):1519-25. PubMed ID: 22895574
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway.
Zhang Z; Liu P; Wang J; Gong T; Zhang F; Ma J; Han N
Med Oncol; 2015 May; 32(5):149. PubMed ID: 25832867
[TBL] [Abstract][Full Text] [Related]
16. UBE2C promotes malignancy of cutaneous squamous cell carcinoma.
Luo R; Bai R; Guo J; Xian N; Zheng Y
Skin Res Technol; 2023 Nov; 29(11):e13526. PubMed ID: 38009019
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis.
Yang X; Cao JL; Yang FN; Li XF; Tao LM; Wang F
Taiwan J Obstet Gynecol; 2021 May; 60(3):480-486. PubMed ID: 33966732
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of CCT3 promotes cervical cancer progression through FN1.
Dou L; Zhang X
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34651664
[TBL] [Abstract][Full Text] [Related]
19. BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways.
Li Y; Cui N; Zheng PS; Yang WT
Oncotarget; 2017 Jul; 8(30):49238-49252. PubMed ID: 28514765
[TBL] [Abstract][Full Text] [Related]
20.
Liu Y; Zhao R; Chi S; Zhang W; Xiao C; Zhou X; Zhao Y; Wang H
Mol Cancer Res; 2020 Feb; 18(2):204-215. PubMed ID: 31662448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
